Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)

At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DX® Breast Cancer Assay Recurrence Score® results. The results showed that adding genomic information provided by the Oncotype DX® Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on standard clinicopathological criteria.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2015
04:23
Color/Sound

Comments are closed.